BridgeBio Oncology Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)256 E. Grand Avenue, Suite 104South San Francisco, CA(Address of principal executive offices) Registrant’s telephone number, including area code: (650) 405-4770 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 7, 2026, the registrant had 80,107,104 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements(unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity(Deficit)Condensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal Proceedings38Item 1A.Risk Factors38Item 2.Unregistered Sales of Equity Securities and Use of Proceeds98Item 3.Defaults Upon Senior Securities98Item 4.Mine Safety Disclosures98Item 5.Other Information98Item 6.Exhibits99Signatures100 BridgeBio Oncology Therapeutics, Inc.Condensed Consolidated Balance Sheets(In thousands, except shares and per share data) BridgeBio Oncology Therapeutics, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In thousands, except shares and per share data) Research and development expenses include related party amounts of $142 and $264 for the three months ended March 31,2026 and 2025, respectively.(1) General and administrative expenses include related party amounts of $40 and $168 for the three months ended March 31, 2026and 2025, respectively.(2) The accompanying notes are an integral part of these condensed consolidated financial statements. Table of Contents BridgeBio Oncology Therapeutics, Inc.Condensed Consolidated Statements of Comprehensive Loss(Unaudited)(In thousands) BridgeBio Oncology Therapeutics, Inc.Condensed Consolidated Statements of Redeemable Convertible Preferred Stockand Stockholders’ Equity(Unaudited)(In thousands, except share data) The accompanying notes are an integral part of these condensed consolidated financial statements. BridgeBio Oncology Therapeutics, Inc.Condensed Consolidated Statements of Cash Flows(Unaudited)(In thousands) BridgeBio Oncology Therapeutics, Inc.Notes to Condensed Consolidated Financial Statements(Unaudited) 1. Organization Description of the Business BridgeBio Oncology Therapeutics, Inc. (“BBOT,” the “Company,” “we,” “our,” or “us”), formerly known as Helix AcquisitionCorp. II (“Helix”), is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small moleculetherapeutics targeting RAS and Phosphoinositide 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco,California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporation, entered into a definitive businesscombination agreement (“Business Combination Agreement”) with Helix, a publicly t